

Figure S1 Comparison of the TMB among FP, HPD, ED, and Control. TMB, tumor mutation burden; FP, fast progression; HPD, hyperprogressive disease; ED, early death.




Figure S2 Genomic comparison of HPD and non-HPD, ED and non-ED, FP and non-FP ICI treated patients from among our 36 tumor samples, as detected by NGS. Control samples consisted of 693 TMB- and histology-matched lung cancer samples (Control) from an internal database. (A) HPD and non-HPD; (B) ED and non-ED; (C) FP and non-FP. The Y-axis represents the mutation frequency of each gene in each group. **, $P < 0.01$; *, $P < 0.05$. TMB, tumor mutation burden; FP, fast progression; HPD, hyperprogressive disease; ED, early death.